O04 How useful is chest X-ray in addition to routine QuantiFERON® in the detection of latent tuberculosis prior to biologics?
Niamh Kearney,Fawad Aslam,Grace Boyd,Natasha Boylan,Emma Laverty,Rosie O’Hare,Victoria Campbell,Susannah Hoey,Donal O’Kane
DOI: https://doi.org/10.1093/bjd/ljae090.004
IF: 11.113
2024-06-28
British Journal of Dermatology
Abstract:Abstract The British Association of Dermatologists (BAD) 2020 psoriasis biologics guidelines recommend routine screening for latent tuberculosis infection (LTBI) prior to treatment, using a QuantiFERON®/interferon-gamma-releasing assay (IGRA), with consideration of local policy on additional screening using chest X-ray (CXR). QuantiFERON® is highly sensitive (approximately 96%) in detecting LTBI, while CXR is both poorly sensitive and poorly specific. CXR is included as a baseline test on the BAD biologics 2014 checklist followed in our trusts. Northern Ireland has the lowest annual incidence of tuberculosis in the UK. The aim of this study was to assess the utility of routine CXR in addition to IGRA before commencing biologics. Patients in two of the five trusts in Northern Ireland receiving biologics that require LTBI screening were identified using trust dermatology biologics databases. Electronic records were reviewed, collecting information on demographics, CXR and IGRA results, and respiratory clinic outcomes. We identified 995 patients, 528 male (53.1%) and 467 female (46.9%), with a mean age of 49.2 years. In total, 685 patients had an IGRA, with 16 of 685 positive (2.3%) and 4 of 685 indeterminate (0.6%). In the four patients with an indeterminate result, just one had a subsequent positive IGRA (0.1%). Overall, 949 patients had a CXR, with 83 of 949 (8.7%) noted to have any abnormality. Twenty-six patients (2.7%) required follow-up imaging, including CXRs (n = 13), computed tomography (n = 10) and echocardiograms (n = 3). Just eight patients had features suggestive of TB on CXR (0.8%). When the χ2-test was used, patients were just as likely to have an abnormal CXR if they had a positive (1 of 16, 6%) or negative IGRA (59 of 666, 8.9%; P = 0.93). Twenty-three patients were referred to the respiratory clinic with a positive IGRA or CXR (2.3%), with 20 patients treated for LTBI (2.0%). Three patients were treated on the basis of a CXR result (0.3%), including two patients without an IGRA and one patient with a negative IGRA. Tuberculosis is uncommon in our dermatology population in Northern Ireland, with just 2% of patients in two trusts treated for LTBI prior to commencing a biologic. QuantiFERON® is a highly sensitive test, detecting LTBI in 1.7% of 665 patients tested in this study. CXR, in contrast, identified changes suggestive of LTBI in 0.8%, with 8.3% noted to have another incidental finding, resulting in a burden of additional imaging requirements. Routine CXR in this cohort did not provide additional diagnostic value in the detection of LTBI. QuantiFERON® alone could be considered sufficient for screening.
dermatology